Loading clinical trials...
Loading clinical trials...
An Open-Label Phase II Study of Lirilumab (BMS-986015) in Combination With 5-Azacytidine (Vidaza) for the Treatment of Patients With Refractory/Relapsed Acute Myeloid Leukemia
Conditions
Interventions
Azacitidine
Lirilumab
Locations
1
United States
M D Anderson Cancer Center
Houston, Texas, United States
Start Date
April 20, 2015
Primary Completion Date
July 12, 2018
Completion Date
July 12, 2018
Last Updated
September 24, 2019
NCT03874052
NCT06484062
NCT06222580
NCT06763341
NCT05589896
NCT03128034
Lead Sponsor
M.D. Anderson Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions